Medical Policy

This document addresses gene therapy for Duchenne muscular dystrophy (DMD), a rare and serious genetic disease affecting muscle strength and movement. Gene therapy is being proposed as a one-time treatment to significantly lessen the severity of DMD. At this time, one gene therapy has been approved by the Food and Drug Administration (FDA) to treat DMD: delandistrogene moxeparvovec-rokl (ELEVIDYS), an adeno-associated virus vector-based gene therapy.

Note: Please refer to the applicable clinical pharmacy criteria used by the Plan for information regarding disease-modifying treatments for DMD; for example: casimersen (Amondys 45), viltolarsen (Viltepso), and golodirsen (Vyondys 53).

Medically Necessary:

A one-time infusion of delandistrogene moxeparvovec-rokl (ELEVIDYS) is considered medically necessary in individuals who meet all of the following criteria:

1. Diagnosis of Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene; and
2. No deletion in exon 8 or exon 9 in DMD gene; and
3. Ambulatory; and
4. Age 4 through 5 years (at least 4 years 0 days and less than 6 years old); and
5. Anti-AAVrh74 total binding antibody titers less than 1:400; and
6. Absence of active infection; and
7. Absence of significant liver dysfunction or disease, defined as at least one of the following:
   1. Preexisting liver impairment; or
   2. Chronic hepatic condition; or
   3. Acute liver disease (e.g., acute hepatic viral infection).

Investigational and Not Medically Necessary:

Delandistrogene moxeparvovec-rokl (ELEVIDYS) is considered investigational and not medically necessary when the criteria above are not met.

Duchenne Muscular Dystrophy (DMD)

Muscular dystrophy (MD) refers to a diverse group of genetic conditions characterized by a decrease in muscle mass over time, including progressive damage and weakness of facial, skeletal, breathing, and heart muscles. Duchenne muscular dystrophy (DMD), the most common and one of the most severe forms of inherited muscular dystrophies, is caused by a mutation of the DMD gene. The DMD gene is responsible for regulating the production of the dystrophin protein that helps keep muscles cells intact. In DMD, the lack of dystrophin weakens the link between the cytoskeleton and sarcolemma which then causes damage to the muscle fibers during contraction and leads to a cycle of muscle cell degeneration, inflammation, fibrosis, and inhibition of muscle fiber regeneration. This process results in progressive deterioration of muscle quality, mass and resulting weakness of facial, limb, respiratory, and cardiac muscles (Darras, 2022; Deng, 2022).

DMD is a rare, X-linked condition, occurring in approximatley1 in 5000 males born worldwide. The DMD gene is located on the X chromosome, and most cases are caused by carriers (mothers) passing the mutation to sons. The remaining one-third of DMD cases are the result of spontaneous mutations that take place on the X chromosome. If a female inherits a dystrophin mutation on one of her X chromosomes, she typically gets sufficient dystrophin from her functioning gene on the other X chromosome but will be a carrier for the disease (Mendell, 2012; Moat, 2013).

While disease progression is variable, muscle weakness is usually noticeable in early childhood. Early signs may include delayed ability to sit, stand, or walk and problems learning to speak. Individuals may be wheelchair-dependent by adolescence. The loss of strength in active breathing muscles leads to respiratory insufficiency and the need for ventilation in the teenage years. Affected individuals infrequently survive beyond the third decade, with respiratory complications and progressive cardiomyopathy being the most common causes of death (Bello, 2016; Landfeldt, 2020; McDonald, 2018; Szabo, 2022).

Several objective measures of motor function have been used to monitor clinical progression for individuals with DMD and to assess the effects of proposed treatments. The North Star Ambulatory Assessment (NSAA) is one such measure that consists of 17 activities including standing, walking, running, and rising from the floor or from a chair, as well as other activities. Each activity is scored as 2 - no limitation, 1 - modified activity but able to independently complete, or 0 - unable to complete the activity independently. The highest achievable score for the 17 activities is 34. The NSAA has been validated in a variety of settings.

The FDA Briefing document for their 2023 Premarket Approval (PMA) for delandistrogene moxeparvovec-rokl states that, in general, individuals with DMD show improvements on the NSAA until about age 6, and then begin to decline. NSAA results can be affected both by the consistency of administration (process-dependent) and by the effort of the participant and/or encouragement or coaching received from a family member, caregiver, or medical team (effort-dependent). Therefore, blinding to treatment assignment is preferred in clinical studies employing the NSAA to limit detection bias.

Gupta and colleagues used several methods to estimate the minimal clinically important difference (MCID) for the NSAA measured in individuals with DMD who were aged 7 - 13 years (Gupta, 2023). Their methods included statistical analysis as well as validating interviews with participants and their parents. Their estimate of the MCID for NSAA for participants aged 7 to 10 years was a score difference of 2.3 - 2.9 points when based on distribution-based estimates of 1/3 standard deviation. The estimated MCID was between 2.9 and 3.5 points when based on the standard error of measurement. When anchored on the 6-minute walk distance (6MWD), the MCID was 3.5 points. The questionnaires showed that the participants rated as significant any loss of function (reduction to a zero score for an activity) or reduction in function (change from a score of 2 to a score of 1) in 1 or 2 activities.

A report published by Ricotti and colleagues in 2016 evaluated the NSAA rate of decline in DMD stratified for different DMD genetic mutations and for the timing of the initiation of glucocorticoid therapy. These investigators used a linearized version of the NSAA. The linearized version converts the NSAA score from a range of 0 - 34 to a range of 0 -100. The authors propose that this conversion improves the comparability of changes across the range. They state that “whereas with the raw score a drop of several points at a mid-level of ability might actually mean a small loss of function (difficulty getting on and off a small step but still independently) and a drop of one point at either end of the scale might suddenly mean a loss of independence rising from the floor or loss of ability to run.” Ricotti, et al., cited a 2013 paper by Mayhew and colleagues to state that the MCID for the linearized NSAA is approximately 10 units. The Ricotti study found an average annual decline in linearized NSAA scores of about 8 units per year after the age of 7. This correlates with a loss of about 4 raw score points per year. Individuals who started glucocorticoid therapy between 3 and 5 years of age experienced an average increase in linearized NSAA score of 3 units/year (1.3 raw unit score increase/year) up until around age 7.

In 2019, Muntoni and colleagues (2019) published results of 395 individuals with DMD in the United Kingdom to establish the natural progression of the NSAA score over time. Participants in the database fell into 1 of 4 clusters: Cluster 1 (25% of all participants) experienced rapid progression with NSAA score falling to <5 by age 10; Cluster 2 included 35% of the total and showed a reduction of their NSAA score to <5 by age 12; Cluster 3 (21%) experience a fall in the NSAA score to <5 by age 14; and Cluster 4 (19%) maintained an NSAA score above 5 past their 15^th birthdays. The authors estimated that approximately 40% of children diagnosed with DMD will continue in a “maturation phase” after the age of 7, during which time their NSAA scores would continue to rise.

In 2016, Mercuri and colleagues published a study evaluating the natural history of performance on the 6MWD test by individuals with DMD. They noted previous studies showing that “rates of change in 6MWD showed significantly greater cross-patient variability than expected, resulting in limited statistical power to measure treatment effects with available sample sizes.” The group studied 96 children aged 5 to 17 years with a mean age of 8.3 years. Almost 65% of the participants had a 6MWD of 350 meters or more at the start of the study. Almost all (96%) were receiving systemic steroids. Similar to the work by Muntoni on the trajectory of NSAA scores, Mecuri found that the observed high variability of the 3-year change in 6MWD could be reduced by grouping participants into trajectory classes. They propose that “an accurate prediction model for trajectories of ambulatory function would enable improved enrichment, stratification, baseline adjustment, and matching in clinical trials with randomized or natural history controls.”

Currently there is no cure for DMD, but improvements in treatment care and management are able to slow disease progression and improve quality of life, thereby prolonging life expectancy for affected individuals (Darras, 2022; Deng, 2022).

Gene Therapy for Duchenne Muscular Dystrophy (DMD)

Delandistrogene moxeparvovec-rokl (ELEVIDYS [Sarepta Therapeutics, Inc. Cambridge, MA]) is a gene therapy for individuals with DMD, initially approved by the FDA under an accelerated approval program on June 22, 2023, for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. ELEVIDYS is administered as a one-time gene transfer infusion using the adeno-associated virus serotype rh74 (rAAVrh74) vector to deliver the micro-dystrophin-encoding gene to skeletal and cardiac muscle tissue. Cells that receive the modified gene produce a micro-dystrophin (a shortened form of the naturally occurring dystrophin protein). Researchers believe that recipients of the modified dystrophin gene will have a milder, Becker-type muscular dystrophy phenotype.

Throughout the FDA approval process, delandistrogene moxeparvovec-rokl has been variably referred to using that name, it’s product development code SRP-9001, rAAVrh74.MHCK7 micro-dystrophin, or its brand name ELEVIDYS. Although there may be differences related to the evolving pharmaceutical production process, this document considers that all 4 names refer to the same product that we will refer to as ELEVIDYS.

Clinical Trial SRP-9001-101 (NCT03375164)

Mendell and colleagues published a study evaluating the safety and biologic efficacy of the administration of ELEVIDYS in individuals with DMD (NCT03375164) (Mendell, 2020). In this single-center, open-label, phase I/IIa, non-randomized, controlled trial, the authors reported on the safety and tolerability of intravenous ELEVIDYS (referred to as rAAVrh74.MHCK7.micro-dystrophin) in individuals with DMD at 52 weeks following treatment.

NCT03375164 was designed to assess the following outcomes:

This study enrolled 4 ambulatory individuals between the ages of 4 to 7 years of age with DMD showing a frameshift mutation contained between exons 18 and 58 (inclusive). These participants were required to have had no preexisting AAVrh74 antibodies, to have received a stable corticosteroid dose for 12 or more weeks, and to be able to cooperate with motor assessment testing. All participants were sufficiently ambulatory to complete several motor assessments. Muscle function was evaluated using the NSAA, a 17-item measure of ambulatory functions with a score range of 0 (unable) to 34 (perfect score).

On day 1 of the trial, all participants received 2.0 × 10¹⁴ vg/kg ELEVIDYS infusion. A total of 53 adverse events (AES) were reported for the 4 participants. Of these AEs, 33 (62%) were considered mild and 20 (38%) were considered moderate. While no serious AEs were reported, 18 AEs were deemed treatment related, the most common of which was vomiting (9 of 18 events [50%]). A total of 3 participants had transiently elevated γ-glutamyltransferase, which resolved with corticosteroids. At 12 weeks, immunohistochemistry of gastrocnemius muscle biopsy specimens demonstrated transgene expression in all participants, with a mean of 81.2% of muscle fibers expressing micro-dystrophin. Western blot revealed a mean expression of 74.3% without fat or fibrosis adjustment and 95.8% with adjustment. At enrollment, the participants’ mean (standard deviation [SD]) NSAA score was 20.5 (3.7) points. The 1-year NSAA score improved 7, 8, 2 and 5 points (mean, 5.5 points) in participants 1, 2, 3 and 4, respectively. All participants had confirmed vector transduction and reduced creatine kinase levels (posttreatment vs baseline) that were maintained for 1 year. The authors concluded that the study demonstrated ELEVIDYS could be delivered safely and resulted in no major AEs. Expression of micro-dystrophin protein and decreased creatine kinase levels were also demonstrated (Mendell, 2020).

Although the results of NCT03375164 demonstrated that the 1-year NSAA score improved by a mean of 5.5 points, it is important to note that a clinically meaningful difference in NSAA scores (approximately 10-point change) was not reached (Ricotti, 2016). In NCT03375164, ELEVIDYS treatment was provided to individuals who were between 4 and 7 years old. Functional performance for individuals in this age range who have DMD would be expected to be improving. As previously noted, blinding to treatment assignment is preferred in clinical studies employing the NSAA.

Mendell and colleagues reported 4-year outcomes from NCT03375164 in 2024 (Mendell, 2024b). All 4 of the original participants were available for evaluation 4 years after their injection. In the 4-year analysis, a total of 72 AEs were documented for the 4 treated participants. Among these, 18 events (25.0%) were identified as treatment-related adverse events (TRAEs). All TRAEs were either mild, accounting for 14 out of 18 (77.8%), or moderate, accounting for 4 out of 18 (22.2%). All 4 participants experienced vomiting and upper respiratory tract infections. Elevated hepatic enzyme levels occurred in 3 of the 4 participants. Once again, the investigators found no serious AEs or AEs that resulted in study discontinuation. All TRAEs occurred within the first 70 days following infusion and were resolved. After the 70-day post-treatment period, no new TRAEs were reported.

The 4-year outcomes from study NCT03375164 demonstrated sustained improvement in NSAA scores for participants, with score increases of +4.0 for Participant 1, +11.0 for Participant 2, +6.0 for Participant 3, and +7.0 for Participant 4. Additionally, the mean changes from baseline to year 4 were as follows: for time to rise, 0.1 seconds (SD = 0.6); for climbing four stairs, 1.1 seconds (SD = 1.4); for the 100-meter walk/run, 7.0 seconds (SD = 6.0); and for the 10-meter walk/run, 0.3 seconds (SD = 0.5).

The single-center, open-label design of this study, coupled with its small sample size, may limit the generalizability of the findings to broader populations or clinical settings. This study does not provide evidence of effectiveness for non-ambulatory individuals or individuals who receive treatment when more than 7 years old. Larger, controlled and blinded studies are needed to demonstrate clinically meaningful improvement in functionality (U.S. FDA 2023a).

Clinical Trial SRP-9001-102 (NCT03769116)

As part of the unpublished data submitted to the FDA in support of the BLA in SRP-9001-102 (Study 102), researchers reported results of statistical analysis of an ongoing, randomized, double-blind, placebo- controlled, multicenter, 3-part clinical study in 41 ambulatory individuals with DMD with either a confirmed frameshift mutation, or a premature stop codon mutation between exons 18 to 58 in the DMD gene. All participants were 4 years or older and less than 8 years of age at time of infusion in Part 1. The primary objectives of this 3-part study were to evaluate micro-dystrophin expression at 12 weeks following ELEVIDYS infusion as measured by western blot of biopsied muscle tissue expressed as a percent of control (levels of dystrophin in normal participants without DMD or Becker muscular dystrophy [BMD]) and to evaluate the effect of ELEVIDYS on physical function as assessed by the NSAA over 48 weeks. In Part 1, participants were randomized 1:1 to receive either a single intravenous infusion of ELEVIDYS (n=20) or placebo (n=21). The study met its primary biological endpoint of micro-dystrophin protein expression. At Week 12 of Study 102 Part 1, the mean (SD) change from baseline levels of micro-dystrophin (% of control) were 3.6 (5.7), 28.2 (52.2), and 43.4 (48.6) for participants receiving ELEVIDYS-dose level 1 (DL1), ELEVIDYS-dose level 2 (DL2), and ELEVIDYS-dose level 3 (DL3), respectively. The study did not demonstrate a statistically significant change in NSAA from baseline to Week 48 after treatment (U.S. FDA 2023a).

Age is known to be a critical prognostic factor in the progression of DMD. Sarepta Therapeutics conducted a subgroup analysis to further evaluate the treatment effect of ELEVIDYS on NSAA scores from baseline to Week 48 by stratifying participants into two age groups: 4-5 years old and 6-7 years old. The exploratory subgroup analyses demonstrated that for individuals in the age 4-5 years cohort, the least square (LS) mean changes (standard error [SE]) in NSAA total score from baseline to Week 48 were 4.3 (0.7) and 1.9 (0.7) points for the ELEVIDYS and placebo group, respectively. For participants 6-7 years of age, the LS mean changes (SE) in NSAA total score from baseline to Week 48 were -0.2 (0.7) and 0.5 (0.7) points for the ELEVIDYS and placebo group, respectively. The analyses suggested that participants 4-5 years old receiving ELEVIDYS did better than the participants receiving placebo; however, individuals 6 to 7 years old who received ELEVIDYS demonstrated no improvement in NSAA and did worse than those receiving placebo. This raises the questions of whether ELEVIDYS only benefits ambulatory individuals below a certain age or above some threshold functional status. The data suggests a potential benefit of treatment with ELEVIDYS in the 4-5 years of age cohort, but potentially no benefit in individuals 6-7 years of age (U.S. FDA 2023a).

A significant limitation in Study 102 Part 1 resulted from shortcomings in dose determination, discovered following subsequent analysis that revealed three different doses of ELEVIDYS were administered to the 20 participants in the active treatment group: 6 participants received one-half the intended dose, 6 participants received two-thirds the intended dose, and 8 participants received the full intended dose.

In Part 2, which was also blinded, participants who received placebo in Part 1 received ELEVIDYS and those that had previously received ELEVIDYS received a placebo infusion. All participants were followed for another 48 weeks while safety and efficacy were evaluated. Two participants had substantially high micro-dystrophin baseline values which, according to Sarepta Therapeutic’s BLA application, may have been caused by baseline expression of a nonfunctional truncated form of dystrophin resulting from participant’s specific mutations. These two participant’s micro-dystrophin expression results were excluded from analysis. At Week 12 of Part 2, the mean (SD) change from baseline levels of the micro-dystrophin (% of control) were 10.6 (17.0), 10.4 (14.7), and 43.5 (55.6) for participants receiving ELEVIDYS-DL1, ELEVIDYS-DL2, and ELEVIDYS-DL3, respectively. ELEVIDYS-treated participants from the placebo crossover group (n=20, aged 5-8 at time of dosing ELEVIDYS) scored a statistically significant 2.0 points higher on the mean NSAA at 48 weeks compared to propensity-score weighted external controls (p value=0.0009). Mean NSAA scores from these Part 2 participants improved 1.3 points from baseline for the ELEVIDYS-treated group, and the NSAA scores in the external control group (n=103) declined 0.7 points from baseline. The mean age of the participants who received ELEVIDYS was 7.24 years of age.

Clinical Trial SRP-9001-103 (NCT04626674, ENDEAVOR trial)

Study 103 (ENDEAVOR) is an open-label, Phase 1b study evaluating over a 5-year (260 weeks) period the safety of and expression from ELEVIDYS (referred to as SRP-9001 in this trial) in males at least 3 years of age with DMD. The primary outcome was the change from baseline in the quantity of micro-dystrophin protein expression at week 12 as measured by western blot (time frame from baseline to week 12). The study was first posted to clinicaltrials.gov in November, 2020, and has a targeted enrollment of 58 individuals across 7 cohorts. The estimated study completion date is January 2028 (U.S. FDA 2023a).

The ENDEAVOR trial has the following cohorts:

Cohort 1: Ambulatory males aged ≥4 to <8 years (N = 20)
Cohort 2:Ambulatory patients aged ≥8 to <18 years (N = 7)
Cohort 3: Non-ambulatory patients of all ages (N = 6)
Cohort 4: Ambulatory patients aged ≥3 to <4 years (N = 7)
Cohort 5: Patients with mutations in exons 1 to 17 (excluding deletions in exons 9 to 13)

• 5a: Ambulatory patients aged ≥4 to <9 years (N = 6)
• 5b: Non-ambulatory patients of all ages (N = 2)

Cohort 6: Ambulatory patients aged ≥2 to <3 years (Target N = 6)
Cohort 7: Non-ambulatory patients (Target N = 4 to 6)

Zaidman and colleagues (2023) reported 1-year interim results for individuals in Cohort 1 of the ENDEAVOR trial. Their report described results for 20 participants with genotype-confirmed DMD who received a single intravenous infusion of ELEVIDYS at a dose of 1.33 x 10¹⁴ vg/kg. The mean age at enrollment was 5.8 years, with a baseline NSAA total score of 22.1. The study declared the following outcomes for evaluation:

At 12 weeks post-treatment, muscle biopsy revealed a significant increase in micro-dystrophin expression, reflecting 54.2% of normal control protein. This finding was confirmed by immunofluorescence that also showed correct localization of micro-dystrophin in the sarcolemma. Vector shedding peaked 1 day after treatment in saliva and urine, and 2 weeks after treatment in stool.

The safety profile reported 181 AEs for the 20 participants, with 177 identified as treatment-emergent and 105 considered treatment-related. Most AEs were mild to moderate, with vomiting occurring in 55% of cases, predominantly within the first 90 days after treatment. There were no deaths or permanent discontinuations.

Functional improvements were noted as the NSAA total score increased from 22.1 to 26.1 at one year, with a mean change of +4.0 points (p < 0.0001). Timed function tests indicated enhancements in various assessments. Use of propensity-matched historical controls for the NSAA assessment makes it difficult to determine how much of the observed functional improvement was a result of this study’s interventions and how much was due to the typical functional development expected in individuals within the study's age range. The results of these exploratory outcomes need confirmation in follow-up studies.

The study concluded that ELEVIDYS demonstrated significant micro-dystrophin expression and presented a tolerable safety profile, indicating potential benefits for stabilizing DMD progression. Further investigations are ongoing to substantiate these findings and explore long-term impacts.

Clinical Trial SRP-9001-301 (NCT05096221, Embark trial)

The EMBARK trial (NCT05096221) is a multinational, randomized, double-blind, placebo-controlled, 2-part trial evaluating the use of ELEVIDYS to treat DMD. The study enrolled males aged 4 to under 8 years with a definitive DMD diagnosis. In Part 1, participants were randomized to receive treatment with ELEVIDYS or with placebo and were followed for 52 weeks. In Part 2, the individuals who received placebo in Part 1 were offered the opportunity to receive ELEVIDYS.

Mendell, et al., reported the results of EMBARK’s Part 1 (Mendell, 2025). The study had screened 173 individuals. Of those, 131 met the following clinical entry criteria:

• Male at birth, ambulatory, and aged between 4 to under 8 years at the time of randomization.
• A confirmed diagnosis of DMD based on clinical findings and prior confirmatory genetic testing.
• Ability to cooperate with motor assessment testing.
• An NSAA total score greater than 16 and less than 29 at the screening visit.
• TTR from the floor of less than 5 seconds at the screening visit.
• A stable daily dose of oral corticosteroids for at least 12 weeks before screening.
• rAAVrh74 antibody titers of less than 1:400.

The primary outcome of interest in EMBARK’s Part 1 was a change in the NSAA total score over the 1-year study period. This was compared between individuals who received ELEVIDYS and those who received placebo. At week 52, the observed least squares mean (LSM) changes from baseline in the NSAA total score were as follows:

• ELEVIDYS treatment group:           2.57 points (95% CI: 1.80 to 3.34)
• Placebo treated group:                    1.92 points (95% CI: 1.14 to 2.70)

The difference between the groups was 0.65 points (s.e. = 0.55), which was not statistically significant (95% CI: -0.45 to 1.74; P = 0.2441). These findings were consistent across the specified age subgroups and baseline NSAA total score subgroups.

The declared key secondary outcomes showed the following LSM change (95% CI) and between-group differences from baseline to week 52:

For this trial’s population of 131 participants, there were a total of 1,188 reported AEs, encompassing 674 incidents with the administration of ELEVIDYS and 514 with the placebo. As reported by each study site's principal investigator, treatment-related/treatment-emergent AEs (TR-TEAEs) were experienced by 48 participants (76.2%) in the ELEVIDYS group, totaling 235 incidents, mostly occurring within the first 90 days after infusion. Of these, 83.3% were mild to moderate and 98.3% resolved on their own. Unresolved events included irritability (n=2), decreased appetite (n=1), and an erroneous lab result that normalized upon retesting (n=1). SAEs were reported by 14 participants (22.2%), with 10 treatment-related SAEs (TR-SAEs) affecting seven participants (11.1%). No clinically significant complement-mediated AEs or cases of thrombotic microangiopathy occurred. There were also no AEs leading to discontinuation from the study or resulting in death. The most common TR-TEAEs observed in the ELEVIDYS cohort were vomiting (54.0%), nausea (31.7%), and decreased appetite (27.0%). Liver enzyme elevations were transient, resolving spontaneously or with adjusted corticosteroid treatment, and no progression to liver failure was detected. Adjustments in corticosteroid administration post-infusion were based on significant liver function abnormalities.

Within this group, acute liver injury, myocarditis, and other TR-SAEs like nausea and vomiting were reported early after infusion and resolved. The authors offered comprehensive narratives for these TR-SAEs. A notable instance of myositis was documented on day 92 post-infusion in a participant with specific genetic deletions, resolving with treatment on day 108. This event, characterized by elevated creatine kinase levels, was distinguished from immune-mediated myositis by its timing and mild nature.

In the placebo group, 17 participants (27.4%) encountered 43 TR-TEAEs and 5 participants (8.1%) reported 9 SAEs, which included conditions such as COVID-19 and influenza. None of these were treatment-related SAEs.

EMBARK Part 1 had several strengths including its relatively large study population, multinational design, and placebo control. Although the study was formally blinded, the frequent occurrence of vomiting, nausea, and decreased appetite may have indicated group allotment to the participants, their families, or the investigators. As previously noted, blinding is important in studies using NSAA as an outcome measure. Additionally, TTR was a key secondary outcome but is also a component of the NSAA, the key primary outcome.

The EMBARK Part 1 authors concluded that ELEVIDYS “did not show a statistically significant difference compared to placebo in the primary endpoint at week 52. Key secondary endpoints and other functional endpoints numerically favored [ELEVIDYS] in the overall population and age subgroups, although no statistical significance can be claimed.”

As of April, 2025, the outcomes of EMBARK part 2 have not been published.

Micro-dystrophin as a Surrogate Biomarker

In preparation for its Cellular Tissue and Gene Therapy Advisory Committee meeting, the FDA issued a briefing document. The document noted that, “measurement of levels of Sarepta’s micro-dystrophin in muscle tissue only provides information about expression of the transgene product in cells transduced by ELEVIDYS, rather than insight into a pharmacologic effect on a biomarker in the pathway of the disease”. The FDA document cautioned that the wild-type (naturally occurring) dystrophin protein not only serves as a shock absorber, but may play an important scaffolding role and helps to recruit potassium, sodium and calcium channels as well as neuronal nitric oxide synthase (a protein known to play a role in the protection of muscle cells and in the control of local blood flow by antagonizing sympathetic vasoconstriction) and signaling proteins (for example, kinases). Sarepta’s abbreviated micro-dystrophin lacks key regions such as those binding neuronal nitric oxide synthase and alpha-syntrophin, and the areas that recruit signaling molecules and ion channels. Therefore, it is unclear to what extent Sarepta’s micro-dystrophin is functionally similar to wild-type dystrophin or to shortened forms of dystrophin in individuals with BMD (U.S. FDA 2023a).

FDA Cellular Tissue and Gene Therapy Advisory Committee Findings

On May 12, 2023, the FDA’s Advisory Committee was presented with clinical evidence, including clinical testimony from providers, individuals with DMD, and their families. The sponsor presented materials supporting the argument that the expression of ELEVIDYS in the participants’ cells was a reasonable endpoint likely to predict clinical benefit, that risks were monitorable and manageable, and that the totality of clinical evidence with appropriate clinical trial comparators was sufficient to support accelerated approval. The sponsor also told the committee that waiting for additional confirmatory data would lead to additional muscle loss in children who might otherwise receive treatment. The available therapies that address the underlying cause of disease (four exon-skipping drugs) only treat a small percentage of individuals with DMD harboring specific gene mutations. At the conclusion of the meeting, the committee voted 8-6 to recommend accelerated approval.

The FDA approved the expanded indication on June 20, 2024, to include non-ambulatory individuals at least 4 years of age who have a mutation in their DMD gene. The expanded indication does not have an upper age limit. The decision memo from the director of FDA’s Center for Biologics Evaluation and Research (CBER) refers to evidence provided by Study 301 and Study 103 described above. While acknowledging that the primary endpoint in Study 301 (change in NSAA from baseline to week 52) did not show a statistically significant difference between treated individuals and controls, the director approved the manufacturer’s request for an expanded indication. The director cited changes in secondary outcomes as the basis for this decision. Of note, the trial was not designed to evaluate these secondary outcomes. These secondary outcome changes included a 0.64 second reduction in the time to rise from the floor (TTR) and a 0.42 meter/second increase in the 10 minute walk/run test (10MWR). The director cited data from Duong (2021) showing that the MCID for the TTR is 0.026 rise/s and, for the 10MWR, the MCID is 0.138 m/s.

CBER’s director issued these concluding statements:

Overall, the demonstrated benefits of ELEVIDYS in the treatment of ambulatory individuals, and the expected benefits of ELEVIDYS in non-ambulatory individuals, with DMD over 4 years of age who are eligible to receive this therapy in improving key functional endpoints such as the ability to stand, walk, or climb stairs, outweigh the risks. The benefit to risk considerations are favorable taking into account the existing uncertainties, such as the ultimate duration of response. Although it might be argued that other gene therapy products in development may prove superior to ELEVIDYS in future clinical trials, these products have yet to receive regulatory approval. During this time, the availability of this gene therapy option may help slow or prevent irreversible decline that might otherwise occur in both ambulatory and non-ambulatory individuals, particularly since the latter have few or no alternative treatments available to address their imminent further decline in function over time (US FDA CBER, 2024)

In making this decision to approve the request for expanded indications, CBER’s director overruled the recommendation of the Office of Clinical Evaluation in their Office of Therapeutic Products (OCE-OTP) which had conducted FDA’s technology assessment for the request. CBER’s OCE-OTP director’s summary of that office’s evaluation included this statement:

[T]he results of Study 301 do not constitute substantial evidence of effectiveness. The trial was designed to show a statistically significant difference in the mean change in NSAA total score from baseline to Week 52 in the intention-to-treat population. The study was designed in keeping with accepted standards for statistical rigor for regulatory purposes, with a less than 5% chance that the result would (falsely) show a difference (i.e., that the Elevidys group performed better or worse than the placebo group) when no difference exists, also known as Type 1 error. The Applicant conducted analyses of additional physical function outcome measures and also conducted analyses in age-defined subgroups in Study 301 without controlling for Type 1 error. Given the exploratory nature of these analyses, they are considered potentially hypothesis generating but the results do not constitute substantial evidence of effectiveness due to the high likelihood that observed differences between the treatment groups may be due to chance.

The OCE-OTP director made the following recommendation regarding the request for expanded indications:

Specifically, it is my assessment that the data submitted in the sBLA:

• do not verify the clinical benefit of Elevidys in ambulatory boys aged 4-5 years (i.e., the group for which accelerated approval was granted by Center Director override of the review team and senior CBER leadership recommendation),
• do not demonstrate the benefit of Elevidys in ambulatory patients greater than age 5 years of age, or
• do not demonstrate the benefit of Elevidys in non-ambulatory patients of any age.

Potential Benefits, Risks, and Uncertainties of ELEVIDYS

The potential benefits of gene therapy for DMD include a delay in disease progression, greater life expectancy and improved quality of life. While the overall results from clinical trials (SRP-9001-102) show only a modest response to treatment in the younger age group (age 4-5), treating physicians and parents report cases of exceptional responses.

The administration of ELEVIDYS is not without risk and some uncertainties. In clinical studies, elevated liver function tests (including increases in GGT, GLDH, ALT, AST, or total bilirubin) were commonly reported within 8 weeks following ELEVIDYS infusion. The majority of cases were asymptomatic, and all cases resolved spontaneously or with systemic corticosteroids and resolved without clinical sequelae within 2 months. There were no reported cases of liver failure. Practitioners are advised to perform liver enzyme test prior to the administration of ELEVIDYS and to monitor liver function with clinical exam, total bilirubin and GGT weekly for the first 3 months following ELEVIDYS infusion.

In clinical trials, immune-mediated myositis was also observed approximately 1 month following ELEVIDYS infusion in participants with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms included severe muscle weakness, including dysphagia, dyspnea and hypophonia. In a life-threatening case of immune-mediated myositis, symptoms resolved during in-patient hospital care, and while muscle strength gradually improved, it did not return to baseline level. It is believed that these immune reactions may be due to a T-cell based response from lack of self-tolerance to a particular region encoded by the transgene corresponding to exons 1-17 of the DMD gene. Currently, there are limited data available for ELEVIDYS treatment in individuals with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Individuals with deletions in these particular regions may be at risk for a severe immune-mediated myositis reaction. The product label cautions that ELEVIDYS is contraindicated in individuals with any deletion in exon 8 and/or exon 9 in the DMD gene due to the elevated risk for a severe immune-mediated myositis reaction.

Another uncertainty is the possibility that individuals who take the product may not be able to receive another more effective gene therapy using the same vector in the future. It is also unclear whether individual factors, such as age at treatment and severity of disease are predictive of response, or whether the treatment provides a long-term, durable benefit. Furthermore, muscle cell turnover is likely to dilute production of micro-dystrophin protein expression over time (Elangkovan, 2021).

In 2023, Lek and colleagues reported the death of a 27-year-old individual with DMD due to a severe immune response following treatment with an intravenous AAV9 vector carrying the CRISPR-transactivator therapeutic agent (CK8e.dSaCas9.VP64.U6.sgRNA). Unlike ELEVIDYS, this agent employs in-vivo gene-editing methods using CRISPR-Cas9, although both share the use of an rAAV vector. Lek et al. noted:

Another hurdle for rAAV gene therapy for DMD is the high dose of rAAV that is required to transduce the extensive mass of tissue that makes up the cardiac and skeletal musculature. The doses of rAAV used in clinical trials for DMD have ranged from 5×10¹³ to 2×10¹⁴ vector genomes (vg) per kilogram of body weight. After treatment with doses within this range, a number of toxic syndromes have been observed, including hepatotoxic effects, often linked to an effector T-cell response to capsid or transgene product; thrombocytopenia and thrombotic microangiopathy, sometimes associated with renal toxic effects in an atypical hemolytic uremic syndrome; and cardiac toxic effects.

This information is relevant for considering treatments for older individuals with rAAV vector therapies, as they generally require higher rAAV doses based on their weight, compared to the younger age group of 4 to 5 years for which safe use of ELEVIDYS has been reported.

On March 18, 2025, Sarepta Pharmaceuticals issued a community letter announcing that a teenager who had received ELEVIDYS treatment for DMD died after suffering acute liver failure. In their letter, Sarepta acknowledged that acute liver failure “is a known possible side effect of ELEVIDYS and other AAV mediated gene therapies” (Sarepta, 2025).

Summary

DMD is a progressive and fatal condition. Gene therapy has the potential to delay disease progression for DMD with a single treatment, and possibly provide a durable cure. The available peer-reviewed, published literature on the use of ELEVIDYS as a gene therapy treatment for DMD is limited. Other data presented with the accelerated approval application demonstrated improvements in surrogate biomarkers. Clinical improvement was limited to a subgroup analysis of 4-5-year-olds based on NSAA scores. The paucity of clinical data and the short follow-up period raise concerns. Nevertheless, the lack of any other effective treatment, DMD’s inexorable and universally fatal course, promising results from a small number of treated 4-5-year-old boys, and the experience of some treating physicians and patients, make it reasonable to offer treatment to that group while awaiting outcomes from larger trials and long-term follow-up.

While there are limited clinical data, sufficient scientific evidence permits reasonable conclusions that treatment with ELEVIDYS increases the expression of the ELEVIDYS micro-dystrophin protein in ambulatory individuals with DMD aged 4 to 5 years with a confirmed mutation in the DMD gene in a manner that appears likely to improve physical function and mobility.

At this time, there is insufficient credible evidence in the published peer-reviewed literature to demonstrate ELEVIDYS infusion improves net health outcomes for non-ambulatory individuals or for individuals outside of the 4 to 5 years age group.

Duchenne Muscular Dystrophy

DMD is inherited in an X-linked recessive pattern, occurring almost exclusively in males, though females may infrequently be affected. DMD is completely penetrant in males. In heterozygous females, penetrance varies and may depend in part on patterns of X-chromosome inactivation. Approximately 30% of cases are due to new mutations and may occur in individuals who do not have a family history of DMD. DMD does not display a predilection for any race or ethnic group (Darras, 2022).

A diagnosis of DMD is made based upon a thorough clinical evaluation, a detailed patient history, and specialized tests including molecular genetic tests. Molecular genetic tests (frequently using blood or muscle cell samples) involve the examination of deoxyribonucleic acid (DNA) to identify single point mutations, deletions, or duplications. These techniques can also be used to diagnosis DMD prenatally. When genetic tests are not informative, tissue biopsy may reveal characteristic changes to muscle fibers. Creatine kinase testing can be used to confirm that muscle is inflamed or damaged, but cannot definitively diagnose DMD. Additionally, other techniques such as immunofluorescence, immunostaining, or Western blot (immunoblot) can be performed on muscle samples to identify the presence and levels of specific proteins within cells (Darras, 2022; NORD, 2016).

Standard therapies used to treat and manage DMD are aimed at the specific symptoms. Treatment options generally include physical therapy and active and passive exercise to build muscle strength and prevent contractures. Surgery may be recommended in select individuals to treat scoliosis or contractures. Braces may be employed to prevent the development of contractures. The use of mechanical aids (e.g., canes, braces, and wheelchairs) may be necessary to assist with ambulation. Corticosteroids may be used to slow the progression of muscle weakness in affected individuals and delay the loss of ambulation. Medications for cardiac function, as well as tracheostomy and assisted ventilation to support respiratory function may also be used (Darras, 2022; NORD, 2016).

More recently, the FDA approved the use of several exon skipping, disease-modifying treatments for a subset of individuals with specific DMD mutations. Exon skipping treatments allow the body to "skip over" errors in the dystrophin gene to make a shorter form of dystrophin. For example:

• Amondys 45 (casimersen) is indicated to treat individuals with DMD who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Amondys 45 2021).   
• Exondys 51 (eteplirsen) injection is indicated for individuals who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping (Exondys 51, 2016).
• Viltepso (viltolarsen) and Vyondys 53 (golodirsen) are indicated to treat individuals with DMD who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping (Viltepso, 2020; Vyondys 53, 2021).

For more information regarding disease-modifying and exon-skipping treatments for DMD (for example: casimersen [Amondys 45], viltolarsen [Viltepso], and golodirsen [Vyondys 53]), please refer to clinical pharmacy criteria.

Gene Therapy for DMD

Gene therapy, also known as gene replacement therapy, introduces or alters genetic material to replace the function of a missing or dysfunctional gene with the goal of lessening or eliminating a disease process that results from genetic dysfunction. A gene may be altered using a “vector” or a “carrier” which is often a virus that has been modified to remove disease-causing genes, or DNA may be changed using genome (gene) editing, a group of technologies that allows genetic material to be added, removed, or altered. There are different approaches to gene therapy including replacing a mutated gene with a healthy gene, inactivating a mutated gene not functioning correctly, or introducing a new gene.

Gene therapy clinical trials for DMD are currently underway. On June 22, 2023, the FDA approved the use of delandistrogene moxeparvovec-rokl (ELEVIDYS) gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene.

Ambulatory: Able to walk, with or without an assistive device, such as a cane or walker (in contrast to “non-ambulatory”: unable to walk and requiring use of a wheelchair on a regular basis).

Adeno-associated virus (AAV): A small virus that infects humans and is not known to cause disease. Modified (non-replicating) AAVs are frequently used as viral vectors for gene therapy.

Becker muscular dystrophy (BMD): A type of muscular dystrophy that is similar to but not as severe as DMD. BMD has a later onset and milder symptoms than DMD but can affect the heart in a manner similar to DMD.

Cytoskeleton: A complex and dynamic network of proteins and filaments in the cytoplasm of many cells. The cytoplasm supplies structural support and transport for the cell and its parts.

Dystrophin: A protein that is required for muscles to function properly. This protein is missing or found in inadequate amounts in individuals with DMD.

Fibrosis: Thickening and scaring of tissue.

Gene replacement therapy: A medical treatment that introduces or alters genetic material to replace the function of a missing or dysfunctional gene with the goal of lessening or eliminating a disease process that results from genetic dysfunction; also known as gene therapy.

Handheld dynamometry: A small, portable device used to evaluate muscle strength.

North Star Ambulatory Assessment (NSAA): A 17-item rating scale that is frequently used in clinical trials to evaluate and measure motor function.

Phenotype: Observable traits or characteristics in an individual that result from having particular genes (in other words, genotype) and from the interaction of the genotype with the environment.

Sacrcolemma: The cell membrane that encases a skeletal muscle fiber, also referred to as the myolemma.

Surrogate endpoint: A marker, such as a physical sign, laboratory measurement, or radiographic image or biomarker that is “reasonably likely” to predict clinical benefit, but in and of itself does not measure clinical benefit (such as changes in survival or symptoms).

Transgene: A gene that is removed from one organism and transferred to another. The transgene consists of a segment of DNA which contains instructions for the production of a specific functional protein.

X-linked recessive trait: A mutation in the gene on the X-chromosome. The phenotype is always expressed in males (who have only one X chromosome) and in females who have mutations in both of their X chromosomes.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:

When services are Investigational and Not Medically Necessary:
For the procedure code listed above when criteria are not met or for all other diagnoses not listed.

Peer Reviewed Publications:

1. Bello L, Morgenroth LP, Gordish-Dressman Het al. CINRG investigators. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016; 87(4):401-409.
2. Bourke JP, Bueser T, Quinlivan R. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database Syst Rev. 2018; 10(10):CD009068.
3. Deng J, Zhang J, Shi K, Liu Z. Drug development progress in Duchenne muscular dystrophy. Front Pharmacol. 2022; 13:950651.
4. Duong T, Canbek J, Birkmeier M, et al.; CINRG-DNHS Investigators. The minimal clinical important difference (MCID) in annual rate of change of timed function tests in boys with DMD. J Neuromuscul Dis. 2021; 8(6):939-948.
5. Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021; 8(s2):S303-S316.
6. Emery N, Strachan K, Kulshrestha R, et al. Evaluating the feasibility and reliability of remotely delivering and scoring the North Star Ambulatory Assessment in ambulant patients with Duchenne muscular dystrophy. Children (Basel). 2022; 9(5):728.
7. Goncalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017; 15(3):369-375.
8. Landfeldt E, Thompson R, Sejersen T, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020; 35(7):643-653.
9. Lek A, Wong B, Keeler A, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy. N Engl J Med. 2023; 389(13):1203-1210.
10. Mayhew AG, Cano SJ, Scott E, et al.; North Star Clinical Network for Neuromuscular Disease. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol. 2013; 55(11):1046-1052.
11. McDonald CM, Gordish-Dressman H, Henricson EK, et al. CINRG investigators for PubMed. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids. Neuromuscul Disord. 2018; 28(11):897-909.
12. Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025; 31(1):332-341.
13. Mendell JR, Proud C, Zaidman CM, et al. Practical Considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr Neurol. 2024a; 153:11-18.
14. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled Trial. JAMA Neurol. 2020; 77(9):1122-1131.
15. Mendell JR, Sahenk Z, Lehman KJ, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1/2a nonrandomized trial. Muscle Nerve. 2024b; 69(1):93-98
16. Okama LO, Zampieri LM, Ramos CL, et al. Reliability and validity analyses of the North Star Ambulatory Assessment in Brazilian Portuguese. Neuromuscul Disord. 2017; 27(8):723-729.
17. Ricotti V, Ridout DA, Pane M, et al.; UK NorthStar Clinical Network. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016; 87(2):149-155.
18. Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023; 94(5):955-968.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Amondys 45 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; Last updated February 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf. Accessed on April 16, 2025.
2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/home. Accessed on April 16, 2025.
   1. A gene transfer therapy study to evaluate the safety and efficacy of SRP-9001 (delandistrogene moxeparvovec) in participants with Duchenne muscular dystrophy (DMD) (EMBARK). NCT05096221. Available at: NCT05096221. Accessed on April 16, 2025.
   2. A gene transfer therapy study to evaluate the safety of and expression from SRP-9001 (delandistrogene moxeparvovec) in participants with Duchenne muscular dystrophy (DMD) (ENDEAVOR). NCT04626674. Available at: NCT04626674. Accessed on April 16, 2025.
   3. A gene transfer therapy study to evaluate the safety of SRP-9001 (delandistrogene moxeparvovec) in participants with Duchenne muscular dystrophy (DMD). NCT03375164. Available at: NCT03375164. Accessed on April 16, 2025.
   4. A randomized, double-blind, placebo-controlled study of SRP-9001 (delandistrogene moxeparvovec) for Duchenne muscular dystrophy (DMD). NCT03769116. Available at: NCT03769116. Accessed on April 16, 2025.
3. Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. 2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023.
4. Elevidys (delandistrogene moxeparvovec-rokl) [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc.; June 2024. Available at: https://www.fda.gov/media/169679/download. Accessed April 16, 2025.
5. Exondys 51 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; Last updated September 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf. Accessed on April 16, 2025.
6. Federal Register. Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry; Availability. Notice October 24, 2022. 87 FR 64234. Available at: https://www.govinfo.gov/content/pkg/FR-2022-10-24/pdf/2022-23057.pdf. Accessed on April 16, 2025.
7. Lee BH. The Dystrophinopathies. Continuum (Minneap Minn). 2022; 28(6):1678-1697.
8. Sarepta (2021c). Sarepta therapeutics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy, SRP-9001, demonstrates robust expression and consistent safety profile using Sarepta’s commercial process material. Sarepta therapeutics. Available at: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-investigational-gene-therapy-treatment Accessed April 16, 2025.
9. Sarepta (2025). Sarepta Therapeutics Community Letter: ELEVIDYS safety update. March 18, 2025. Available at: https://www.sarepta.com/community-letter-elevidys-safety-update. Accessed on May 1, 2025.
10. U. S. Food & Drug Administration (FDA).
    1. Briefing Document. BLA# 125781. Drug name: delandistrogene moxeparvovec. Released 05/12/2023. Available at: https://www.fda.gov/media/168021/download. Accessed on April 16, 2025.
    2. Center Director Decisional Memo (CBER) - ELEVIDYS (BLA 125781/Amendment 34). Approved June 20, 2024. Available at: https://www.fda.gov/media/179485/download?attachment. Accessed on April 16, 2025.
    3. Development & Approval Process. Drugs. Updated August 8, 2022. Available at: https://www.fda.gov/drugs/development-approval-process-drugs#FDA. Accessed on April 16, 2025.
    4. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular Dystrophy. Released June 22, 2023. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy. Accessed on April 16, 2025.
11. Viltepso [package insert]. Paramus, NJ. NS Pharma, Inc.; Last updated August 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154s000lbl.pdf. Accessed on April 16, 2025.
12. Vyondys 53 [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc. Last updated February 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211970s002lbl.pdf. Accessed on April 16, 2025.

1. Muscular Dystrophy Association. Becker muscular dystrophy (BMD). Last update September 2024. Available at: https://www.mda.org/disease/becker-muscular-dystrophy. Accessed on April 16, 2025.
2. Muscular Dystrophy Association. Duchenne muscular dystrophy (DMD). Available at: https://www.mda.org/disease/duchenne-muscular-dystrophy. Accessed on April 16, 2025.
3. National Center for Advancing Translational Services. Genetic and Rare Diseases Information Center. Duchenne muscular dystrophy. Last updated February 2025. Available at: https://rarediseases.info.nih.gov/diseases/6291/duchenne-muscular-dystrophy. Accessed on April 16, 2025.
4. National Organization for Rare Disorders (NORD). Duchenne muscular dystrophy. Last updated July 15, 2024. Available at: https://rarediseases.org/rare-diseases/duchenne-muscular-dystrophy/. Accessed on April 16, 2025.

Delandistrogene moxeparvovec-rokl (SRP-9001)
Duchenne Muscular Dystrophy
ELEVIDYS
Gene Therapy

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association